Quality Of Cannabis Issued By Government Affecting Scientists’ Research
The quality of the cannabis the United States government provides to scientists may be impacting the results of their studies, experts say. The issue made national headlines after Dr. Sue Sisley, a researcher with the Multidisciplinary Association for Psychedelic Studies (MAPS), shared photos of the marijuana provided by the only facility licensed by the Drug Enforcement Administration to produce cannabis for clinical research. The facility is located at the University of Mississippi and is run by the National Institute on Drug Abuse (NIDA).
Marijuana As A Glaucoma Treatment; Does It Really Work?
Research has shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30%. Despite the findings from early research, very few ophthalmologists support the use of medical cannabis in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with marijuana is that the potential adverse effects, particularly smoking cannabis, outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, which heightens the risk of permanent vision loss.
Marijuana Industry Takes A Step Forward Towards Validity And Long-Term Stability
The marijuana industry is getting ready to take a step forward in its venture for validity and long-term stability. The American Society for Testing and Materials (ASTM International) recently announced that it will put a committee of industry representatives and experts together to create a set of guidelines in six technical areas: Indoor and outdoor horticulture and agriculture, Quality management systems, Laboratory standards, Processing and handling, Security and transportation, Personal training/ assessment and credentialing.